Antipsychotic dosing: still a work in progress.
Gary
G
Remington
D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000494:pharmacology / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000494:pharmacology / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D000077152:Olanzapine; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism; D012720:Severity of Illness Index
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D000068180:Aripiprazole; D000077152:Olanzapine